Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2018

Genmab (Nasdaq:GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 498 million in the third quarter of 2018 compared to USD 317 million in the third quarter of 2017, an increase of 57%.

As quoted in the press release:

The 2018 third quarter net sales were USD 318 million in the U.S. and USD 180 million in the rest of the world.

Johnson & Johnson reported worldwide operational growth (excluding the impact of foreign currency movements) between the two third quarter periods of 60%.The growth was partially offset by a one-time adjustment outside the U.S. related to accruals for retroactive pricing adjustments which negatively impacted this worldwide operational growth by 16 percentage points.

Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

Click here to read the full press release.